Literature DB >> 9920790

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

U Yasar1, E Eliasson, M L Dahl, I Johansson, M Ingelman-Sundberg, F Sjöqvist.   

Abstract

Cytochrome P450 2C9 (CYP2C9) catalysis the metabolism of important drugs such as phenytoin, S-warfarin, tolbutamide, losartan, torasemide, and nonsteroidal anti-inflammatory drugs. A functional polymorphism of the CYP2C9 gene has been described. The variant alleles include CYP2C9*2 having a point mutation in exon 3 causing an Arg144Cys exchange, and CYP2C9*3 with a point mutation in exon 7 resulting in an Ile359Leu exchange. Genotyping of these variant forms was carried out in 430 Swedish healthy volunteers and three different methods were compared. Sequence analysis of the different PCR products revealed that other genes in the CYP2C locus were co-amplified in one of the methods applied, whereas the other two methods were specific for CYP2C9. The frequencies of the CYP2C9*1, CYP2C9*2 and CYP2C9*3 alleles in the population examined were found to be 0.819, 0.107, and 0.074, respectively. The need for careful evaluation of the genotyping procedure by sequence analysis of PCR products is emphasised. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920790     DOI: 10.1006/bbrc.1998.9992

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  64 in total

1.  CYP2C9 polymorphism and warfarin dose requirements.

Authors:  Ann K Daly; Christopher P Day; Guruprasad P Aithal
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

2.  CYP2C9 polymorphisms and CYP2C9*2 genotyping primers.

Authors:  Joyce A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

3.  Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers.

Authors:  Liat Mlynarsky; Idit Bejarano-Achache; Mordechai Muszkat; Yoseph Caraco
Journal:  Eur J Clin Pharmacol       Date:  2011-11-10       Impact factor: 2.953

4.  Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity.

Authors:  Umit Yasar; Marja-Liisa Dahl; Magnus Christensen; Erik Eliasson
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

5.  Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9.

Authors:  Kerenaftali Klein; Ivelina Gueorguieva; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-21       Impact factor: 2.745

6.  Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.

Authors:  Al-Motassem Yousef; Nailya R Bulatova; William Newman; Nancy Hakooz; Said Ismail; Hisham Qusa; Farah Zahran; Nidaa Anwar Ababneh; Farah Hasan; Imad Zaloom; Ghada Khayat; Rawan Al-Zmili; Randa Naffa; Ola Al-Diab
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

7.  CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

Authors:  Han-Jing Cen; Wu-Tao Zeng; Xiu-Yu Leng; Min Huang; Xiao Chen; Jia-Li Li; Zhi-Ying Huang; Hui-Chang Bi; Xue-Ding Wang; Yan-Ling He; Fan He; Rui-Na Zhou; Qi-Shan Zheng; Li-Zi Zhao
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

8.  Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

Authors:  John F Carlquist; Benjamin D Horne; Joseph B Muhlestein; Donald L Lappé; Bryant M Whiting; Matthew J Kolek; Jessica L Clarke; Brent C James; Jeffrey L Anderson
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

9.  CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.

Authors:  Pedro Dorado; Roland Berecz; Maria-Jesús Norberto; Umit Yasar; Marja-Liisa Dahl; Adrián LLerena
Journal:  Eur J Clin Pharmacol       Date:  2003-05-07       Impact factor: 2.953

10.  Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.

Authors:  Julia Kirchheiner; Ingolf Meineke; Nadine Steinbach; Christian Meisel; Ivar Roots; Jürgen Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.